• Susan E Rowell, Eric N Meier, Barbara McKnight, Delores Kannas, Susanne May, Kellie Sheehan, Eileen M Bulger, Ahamed H Idris, Jim Christenson, Laurie J Morrison, Ralph J Frascone, Patrick L Bosarge, M Riccardo Colella, Jay Johannigman, Bryan A Cotton, Jeannie Callum, Jason McMullan, David J Dries, Brian Tibbs, Neal J Richmond, Myron L Weisfeldt, John M Tallon, John S Garrett, Martin D Zielinski, Tom P Aufderheide, Rajesh R Gandhi, Rob Schlamp, Robinson Bryce R H BRH Department of Surgery, University of Washington, Seattle., Jonathan Jui, Lauren Klein, Sandro Rizoli, Mark Gamber, Michael Fleming, Jun Hwang, Laura E Vincent, Carolyn Williams, Audrey Hendrickson, Robert Simonson, Patricia Klotz, George Sopko, William Witham, Michael Ferrara, and Martin A Schreiber.
• Department of Surgery, Oregon Health & Science University, Portland.
• JAMA. 2020 Sep 8; 324 (10): 961-974.

ImportanceTraumatic brain injury (TBI) is the leading cause of death and disability due to trauma. Early administration of tranexamic acid may benefit patients with TBI.ObjectiveTo determine whether tranexamic acid treatment initiated in the out-of-hospital setting within 2 hours of injury improves neurologic outcome in patients with moderate or severe TBI.Design, Setting, And ParticipantsMulticenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency medical services agencies in the US and Canada from May 2015 to November 2017. Eligible participants (N = 1280) included out-of-hospital patients with TBI aged 15 years or older with Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher.InterventionsThree interventions were evaluated, with treatment initiated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309).Main Outcomes And MeasuresThe primary outcome was favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic acid group vs the placebo group. Asymmetric significance thresholds were set at 0.1 for benefit and 0.025 for harm. There were 18 secondary end points, of which 5 are reported in this article: 28-day mortality, 6-month Disability Rating Scale score (range, 0 [no disability] to 30 [death]), progression of intracranial hemorrhage, incidence of seizures, and incidence of thromboembolic events.ResultsAmong 1063 participants, a study drug was not administered to 96 randomized participants and 1 participant was excluded, resulting in 966 participants in the analysis population (mean age, 42 years; 255 [74%] male participants; mean Glasgow Coma Scale score, 8). Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month follow-up. The primary outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84). There was no statistically significant difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -0.9 [95% CI, -2.5 to 0.7]; P = .29), or progression of intracranial hemorrhage (16% vs 20%; difference, -5.4% [95% CI, -12.8% to 2.1%]; P = .16).Conclusions And RelevanceAmong patients with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury compared with placebo did not significantly improve 6-month neurologic outcome as measured by the Glasgow Outcome Scale-Extended.Trial RegistrationClinicalTrials.gov Identifier: NCT01990768.

28 keywords...

hide…